ExpressTec is a privately held biopharmaceutical company whose vision is to improve human longevity and quality of life by developing and commercializing innovative medicines and cell-culture media components derived from ExpressTec.
ExpressTec is a patented, plant-based technology for manufacturing recombinant proteins with a ten-fold higher yield than other plant-based systems. It delivers meaningful and sustainable advantages by enabling the development of product opportunities that were previously inaccessible due to technical and economic constraints. ExpressTec can be used to develop new biotherapeutics, novel vaccines, cell culture media components for cell therapy, gene therapy and vaccine applications, and enzymes.
ExpressTec’s internal therapeutic pipeline is focused on safely improving clinical outcomes in infectious disease and inflammatory disease. Our therapeutic products are based on naturally occurring, orally available proteins that are impractical to source naturally, such as the beneficial components of human colostrum and breastmilk. ExpressTec is leveraging the multiple advantages of ExpressTec to enable cost-effective production of these proteins on a therapeutic scale.
ExpressTec’s technology and model are time-proven, with more than 10 years of experience manufacturing and marketing recombinant proteins for use in biotechnology applications through its subsidiary, InVitria. ExpressTec also provides access to its platform technology through contract manufacturing services.
ExpressTec has an extensive intellectual property portfolio of more than 100 issued patents, exclusive licenses to issued patents, and patents in prosecution. These patents provide long-term sustainable advantage to ExpressTec’s manufacturing technology and product portfolio.